Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Induction of ovulation in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian stimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Induction of spermatogenesis in men with hypogonadotropic hypogonadism
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Metabolized via hepatic and renal pathways; exact enzymes not fully characterized. Clearance involves proteolytic degradation and renal excretion.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 70–80% bound to plasma proteins, primarily albumin.
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Approximately 0.3–0.6 L/kg, indicating distribution primarily into extracellular fluid.
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Subcutaneous: approximately 70% (range 60–80%) relative to intravenous administration.
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min).
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
No specific Child-Pugh based modifications; caution in severe hepatic impairment.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Not indicated for use in children; no established pediatric dosing.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Not indicated for use in elderly patients; no specific dosing recommendations.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
GONAL-F should only be used by physicians experienced in fertility treatment. Ovarian hyperstimulation syndrome (OHSS) is a serious, potentially fatal complication. Patients should be monitored for signs of OHSS. GONAL-F may increase the risk of multiple gestation and pregnancy loss.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Ovarian hyperstimulation syndrome (OHSS): can progress to severe form with respiratory distress, oliguria, and thromboembolism,Ovarian torsion,Multiple pregnancy,Ectopic pregnancy,Pulmonary embolism,Ovarian neoplasia (rare),Hypersensitivity reactions including anaphylaxis
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Hypersensitivity to follitropin alfa or any excipient,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary),Pregnancy and lactation,Ovarian cyst or enlargement of unknown origin
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
No specific food interactions. Maintain adequate hydration to reduce OHSS risk.
No known food interactions.
GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if inadvertent administration occurs during pregnancy, there is a potential risk of luteal phase defect and multiple gestation. Human data on fetal effects are limited; animal studies show no evidence of teratogenicity at clinically relevant doses. No consistent pattern of malformations has been reported.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
It is not known whether follitropin alfa is excreted in human breast milk. Due to its protein nature and high molecular weight (approximately 30 k Da), transfer into milk is likely limited. However, because GONAL-F is typically used in fertility treatments and not during breastfeeding, no specific M/P ratio is available. Caution is advised if use is considered during lactation.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
GONAL-F is contraindicated during pregnancy; therefore, no dosing adjustments during pregnancy are applicable. Treatment should be discontinued if pregnancy is confirmed.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
GONAL-F (follitropin alfa) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicle growth via ultrasound to adjust dosing and reduce OHSS risk. Use the lowest effective dose. Do not administer if ovarian cyst or enlargement is present. LH supplementation may be needed in hypogonadotropic hypogonadism.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Inject subcutaneously as directed; rotate injection sites to avoid lipodystrophy.,Report severe pelvic pain, nausea, weight gain, or shortness of breath immediately (OHSS symptoms).,Missed doses can affect cycle; do not double dose without consulting healthcare provider.,Store vials in refrigerator (2-8°C) before mixing; after mixing, use immediately or store refrigerated for up to 28 days.,Avoid pregnancy tests until instructed; false positives may occur from h CG trigger.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F vs CHORIONIC GONADOTROPIN, answered by our medical review team.
GONAL-F is a Gonadotropin that works by GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F is: Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F is classified as Category C. GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if ina. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.